Showing 37 to 48 of 79 results
NHS England Offers Injectable Cancer Immunotherapy
NHS England becomes the first in Europe to offer injectable nivolumab, an immunotherapy, to treat up to 15,000 cancer patients annually, saving significant time compared to intravenous infusions and improving patient access.
NHS England Offers Injectable Cancer Immunotherapy
NHS England becomes the first in Europe to offer injectable nivolumab, an immunotherapy, to treat up to 15,000 cancer patients annually, saving significant time compared to intravenous infusions and improving patient access.
Progress
40% Bias Score
Immunotherapy Shows Promise in Treating MMR-deficient Solid Tumors
A clinical trial at Memorial Sloan Kettering Cancer Center showed that an immunotherapy treatment led to complete tumor disappearance in all 49 rectal cancer patients and 65% of other cancer patients with a specific genetic mutation (MMR-deficient), avoiding the need for surgery, radiation, and chem...
Immunotherapy Shows Promise in Treating MMR-deficient Solid Tumors
A clinical trial at Memorial Sloan Kettering Cancer Center showed that an immunotherapy treatment led to complete tumor disappearance in all 49 rectal cancer patients and 65% of other cancer patients with a specific genetic mutation (MMR-deficient), avoiding the need for surgery, radiation, and chem...
Progress
40% Bias Score
Pembrolizumab Extends Head and Neck Cancer Remission by 30 Months
A global phase III trial involving 714 patients with newly diagnosed head and neck cancer showed that pembrolizumab combined with standard treatment significantly increased disease-free survival to 60 months compared to 30 months for standard treatment alone.
Pembrolizumab Extends Head and Neck Cancer Remission by 30 Months
A global phase III trial involving 714 patients with newly diagnosed head and neck cancer showed that pembrolizumab combined with standard treatment significantly increased disease-free survival to 60 months compared to 30 months for standard treatment alone.
Progress
40% Bias Score
Keytruda's $30 Billion Success: Revolutionizing Cancer Treatment
Keytruda, Merck's immunotherapy drug, generated nearly $30 billion in 2024 sales, marking a paradigm shift in cancer treatment since its 2014 launch, building upon research dating back to the late 19th century.
Keytruda's $30 Billion Success: Revolutionizing Cancer Treatment
Keytruda, Merck's immunotherapy drug, generated nearly $30 billion in 2024 sales, marking a paradigm shift in cancer treatment since its 2014 launch, building upon research dating back to the late 19th century.
Progress
48% Bias Score
Common Pain Relievers Show Promise in Cancer Prevention and Treatment
Studies show common pain relievers like aspirin, ibuprofen, and diclofenac may prevent cancer recurrence by inhibiting the enzyme cyclooxygenase-1, reactivating T-cells to destroy micrometastases, with effectiveness varying across cancer types and patient genetic factors, although potential side eff...
Common Pain Relievers Show Promise in Cancer Prevention and Treatment
Studies show common pain relievers like aspirin, ibuprofen, and diclofenac may prevent cancer recurrence by inhibiting the enzyme cyclooxygenase-1, reactivating T-cells to destroy micrometastases, with effectiveness varying across cancer types and patient genetic factors, although potential side eff...
Progress
40% Bias Score
Oncolytic Virotherapy Shows Promise in Treating Recurrent Glioblastoma
Oncolytic viruses are demonstrating effectiveness in treating aggressive brain cancers like glioblastoma, with a Biotherapy International patient achieving remission after failing conventional treatments; this targeted approach, using the Omaya reservoir for precise drug delivery, offers improved ou...
Oncolytic Virotherapy Shows Promise in Treating Recurrent Glioblastoma
Oncolytic viruses are demonstrating effectiveness in treating aggressive brain cancers like glioblastoma, with a Biotherapy International patient achieving remission after failing conventional treatments; this targeted approach, using the Omaya reservoir for precise drug delivery, offers improved ou...
Progress
68% Bias Score
Immunotherapy Shows 80% Success Rate in Treating Various Cancers
A Memorial Sloan Kettering study published in The New England Journal of Medicine reveals that immunotherapy successfully treated 80% of patients with various cancer types, including 100% of rectal cancer patients, offering a less toxic alternative to traditional treatments.
Immunotherapy Shows 80% Success Rate in Treating Various Cancers
A Memorial Sloan Kettering study published in The New England Journal of Medicine reveals that immunotherapy successfully treated 80% of patients with various cancer types, including 100% of rectal cancer patients, offering a less toxic alternative to traditional treatments.
Progress
52% Bias Score
Immunotherapy Eliminates Surgery Need in Some Early-Stage Cancers
A new study in the New England Journal of Medicine shows that dostarlimab immunotherapy eliminated the need for surgery in 82 of 103 patients with early-stage cancers with a specific genetic defect; 49 rectal cancer patients avoided surgery, with 92% remaining cancer-free after two years.
Immunotherapy Eliminates Surgery Need in Some Early-Stage Cancers
A new study in the New England Journal of Medicine shows that dostarlimab immunotherapy eliminated the need for surgery in 82 of 103 patients with early-stage cancers with a specific genetic defect; 49 rectal cancer patients avoided surgery, with 92% remaining cancer-free after two years.
Progress
44% Bias Score
Immunotherapy Shows Promise in Treating Mismatch Repair Deficient Cancers
A clinical trial at Memorial Sloan Kettering showed that immunotherapy was highly effective in treating mismatch repair deficient (MMRd) cancers, potentially eliminating the need for surgery, chemotherapy, and radiation for many patients, significantly improving quality of life.
Immunotherapy Shows Promise in Treating Mismatch Repair Deficient Cancers
A clinical trial at Memorial Sloan Kettering showed that immunotherapy was highly effective in treating mismatch repair deficient (MMRd) cancers, potentially eliminating the need for surgery, chemotherapy, and radiation for many patients, significantly improving quality of life.
Progress
44% Bias Score
NHS Fast-Tracks Melanoma Vaccine Access
The NHS will provide fast-tracked access to a new melanoma vaccine, iSCIB1+, for advanced melanoma patients in England, aiming to prevent recurrence and potentially saving lives; up to 10,000 patients will receive personalized cancer treatments by 2030.
NHS Fast-Tracks Melanoma Vaccine Access
The NHS will provide fast-tracked access to a new melanoma vaccine, iSCIB1+, for advanced melanoma patients in England, aiming to prevent recurrence and potentially saving lives; up to 10,000 patients will receive personalized cancer treatments by 2030.
Progress
48% Bias Score
AI System scNET Improves Understanding of Cellular Drug Response
Tel Aviv University researchers developed scNET, an AI system that analyzes single-cell gene activity and interactions to reveal subtle changes in how cells respond to drug treatments, especially in cancer, as published in Nature Methods.
AI System scNET Improves Understanding of Cellular Drug Response
Tel Aviv University researchers developed scNET, an AI system that analyzes single-cell gene activity and interactions to reveal subtle changes in how cells respond to drug treatments, especially in cancer, as published in Nature Methods.
Progress
24% Bias Score
Aspirin Shows Promise in Cancer Fight: Animal Study
Aspirin, a common pain reliever, shows promise in fighting cancer by enhancing the immune system's ability to destroy spreading cancer cells, according to a University of Cambridge animal study, though human trials are needed to confirm its efficacy and safety.
Aspirin Shows Promise in Cancer Fight: Animal Study
Aspirin, a common pain reliever, shows promise in fighting cancer by enhancing the immune system's ability to destroy spreading cancer cells, according to a University of Cambridge animal study, though human trials are needed to confirm its efficacy and safety.
Progress
40% Bias Score
Showing 37 to 48 of 79 results